TY - JOUR
T1 - PD-L1 expression in gastroenteropancreatic neuroendocrine neoplasms grade 3
AU - Ali, Abir Salwa
AU - Langer, Seppo W.
AU - Federspiel, Birgitte
AU - Hjortland, Geir Olav
AU - Grønbæk, Henning
AU - Ladekarl, Morten
AU - Welin, Staffan
AU - Vestermark, Lene Weber
AU - Arola, Johanna
AU - Österlund, Pia
AU - Knigge, Ulrich
AU - Sørbye, Halfdan
AU - Micke, Patrick
AU - Grimelius, Lars
AU - Grönberg, Malin
AU - Janson, Eva Tiensuu
N1 - Funding Information:
This work was supported by the Swedish Cancer Society (ETJ CAN 18 0576, www. cancerfonden.se), the Lions Foundation for Cancer Research at the Uppsala University Hospital (ETJ), the Selander foundation (ETJ) and the foundation for International Studies at the Faculty of Health Science, University of Copenhagen (UK).The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Publisher Copyright:
© 2020 Ali et al.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020
Y1 - 2020
N2 - Gastroenteropancreatic neuroendocrine neoplasms grade 3 (GEP-NENs G3) are rare tumors. These highly aggressive neoplasms are traditionally treated with platinum-based chemotherapy in combination with etoposide. Immune checkpoint proteins such as programmed cell death ligand (PD-L1) may have a role in different cancers allowing them escape the immune system and hence, progress. We aimed to investigate the immunohistochemical expression of PD-L1 in GEP-NEN G3 and evaluate its correlation to clinical parameters. In a cohort of 136 patients, 14 (10%) expressed PD-L1 immunoreactivity; four (3%) patients in the tumor cells and 10 (7%) had immunoreactive immune cells. PD-L1 expression did not correlate to clinical parameters, progression-free survival or overall survival. We conclude that PD-L1 expression is present only in a subset of GEP-NEN G3 patients. Further studies are needed to fully understand the role of PD-L1 in patients with GEP-NEN G3, including the future possibility for treatment with immune checkpoint inhibitors.
AB - Gastroenteropancreatic neuroendocrine neoplasms grade 3 (GEP-NENs G3) are rare tumors. These highly aggressive neoplasms are traditionally treated with platinum-based chemotherapy in combination with etoposide. Immune checkpoint proteins such as programmed cell death ligand (PD-L1) may have a role in different cancers allowing them escape the immune system and hence, progress. We aimed to investigate the immunohistochemical expression of PD-L1 in GEP-NEN G3 and evaluate its correlation to clinical parameters. In a cohort of 136 patients, 14 (10%) expressed PD-L1 immunoreactivity; four (3%) patients in the tumor cells and 10 (7%) had immunoreactive immune cells. PD-L1 expression did not correlate to clinical parameters, progression-free survival or overall survival. We conclude that PD-L1 expression is present only in a subset of GEP-NEN G3 patients. Further studies are needed to fully understand the role of PD-L1 in patients with GEP-NEN G3, including the future possibility for treatment with immune checkpoint inhibitors.
U2 - 10.1371/journal.pone.0243900
DO - 10.1371/journal.pone.0243900
M3 - Article
C2 - 33315908
AN - SCOPUS:85098325552
VL - 15
IS - 12
M1 - e0243900
ER -
